Tumor Biology

, Volume 34, Issue 2, pp 847–851

PTEN protein expression in malignant pleural mesothelioma

  • Vijay Agarwal
  • Anne Campbell
  • Kate L. Beaumont
  • Lynn Cawkwell
  • Michael J. Lind
Research Article

DOI: 10.1007/s13277-012-0615-9

Cite this article as:
Agarwal, V., Campbell, A., Beaumont, K.L. et al. Tumor Biol. (2013) 34: 847. doi:10.1007/s13277-012-0615-9

Abstract

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitutive activation of AKT resulting in cell survival and proliferation. Small studies reported that PTEN protein expression is rarely lost in mesothelioma whilst a larger study demonstrated prognostic significance of PTEN protein expression status with absence in 62 % of cases. We aimed to analyse PTEN protein expression in mesothelioma. Immunohistochemical analysis was performed in 86 archival mesothelioma samples to determine the PTEN protein expression status and statistical analysis was performed to identify any prognostic significance. Mesothelial cells in normal pleura demonstrated positive staining for PTEN protein and served as a positive reference. For mesothelioma samples, the expression of PTEN protein was scored as 0 (negative), 1 (intensity less than that of positive normal pleura reference slide) and 2 (intensity equal to or greater than positive normal pleura reference slide). A total of 23/86 (26.7 %) scored 0, 23/86 (26.7 %) scored 1 and 40/86 (46.5 %) scored 2 for PTEN expression. Univariate analysis demonstrated that lack of PTEN expression was not associated with survival. PTEN protein expression was undetectable in 26.7 % of mesothelioma samples; however, no prognostic significance was identified. Absence of PTEN protein may result in activation of the PI3K/AKT/MTOR pathway. Targeting this pathway with inhibitors further downstream of PTEN may provide a potential therapeutic target in selected patients.

Keywords

AKT Immunohistochemistry Mesothelioma MTOR pathway PTEN 

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Vijay Agarwal
    • 1
    • 2
    • 3
  • Anne Campbell
    • 1
    • 4
  • Kate L. Beaumont
    • 1
  • Lynn Cawkwell
    • 1
    • 2
    • 5
  • Michael J. Lind
    • 1
    • 2
    • 3
  1. 1.Cancer Biology Proteomics GroupPostgraduate Medical Institute of the University of HullHullUK
  2. 2.Hull York Medical SchoolHullUK
  3. 3.Queens Centre for Oncology and HaematologyHull and East Yorkshire NHS TrustHullUK
  4. 4.Histopathology DepartmentHull and East Yorkshire NHS TrustHullUK
  5. 5.Research LaboratoriesCastle Hill HospitalHullUK

Personalised recommendations